A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR -mutated lung adenocarcinoma

We aimed to develop a new mutation-predictive scoring system to use in screening for -mutated lung adenocarcinomas (lacs). The study enrolled 279 patients with lac, including 121 patients with wild-type tumours and 158 with -mutated tumours. The Student t-test, chi-square test, or Fisher exact test...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current oncology (Toronto) 2018-04, Vol.25 (2), p.e132-138
Hauptverfasser: Cao, Y, Xu, H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 138
container_issue 2
container_start_page e132
container_title Current oncology (Toronto)
container_volume 25
creator Cao, Y
Xu, H
description We aimed to develop a new mutation-predictive scoring system to use in screening for -mutated lung adenocarcinomas (lacs). The study enrolled 279 patients with lac, including 121 patients with wild-type tumours and 158 with -mutated tumours. The Student t-test, chi-square test, or Fisher exact test was applied to discriminate clinical and computed tomography (ct) features between the two groups. Using a principal component analysis (pca) model, we derived predictive coefficients for the presence of mutation in lac. The mutation-predictive score includes sex, smoking history, homogeneity, ground-glass opacity (ggo) on imaging, and the presence of pericardial effusion. The pca predictive model took this form: [Formula: see text]Model scores ranged from 79 to 147. The area under the receiver operating characteristic curve was 0.752 [95% confidence interval (ci): 0.697 to 0.801] in the lac population at the optimal cut-off value of 109, and the sensitivity and specificity were 68.4% (95% ci: 60.5% to 75.5%) and 74.4% (95% ci: 65.6% to 81.9%) respectively. The mutation risk scoring system based on clinical data and ct features is noninvasive and user-friendly. The model appears to frame a positive predictive value and was able to determine the value of repeating a biopsy if tissue is limited.
doi_str_mv 10.3747/co.25.3805
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5927792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2034289056</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-c8bcbb2fc5dc9b7860f0b2032b74eae8c42af646d9efdc88c8b936232c926e773</originalsourceid><addsrcrecordid>eNpVkdFqFTEQhoMotlZvfADJpQh7zCa7m82NUEpbhYIgeh1mJ7Onkd1kTbKV8wY-tntoLfVqhvm_-WfgZ-xtLXZKN_ojxp1sd6oX7TN2Wuu6r7SW5vmT_oS9yvmnEEpprV-yE2l0bRqlT9mfcx7oN18SOY_F3xHPGJMPe54PudDMB8jkeAwcJx88wsQdFOAQHMc4L2vZ1BLnuE-w3B74SFDWRJmPMXHnYR9iPrpdXl9949W8FjguTOs2AkchIiT0Ic7wmr0YYcr05qGesR9Xl98vPlc3X6-_XJzfVKgaWSrsBxwGOWLr0Ay678QoBimUHHRDQD02Esau6Zyh0WHfb7xRnVQSjexIa3XGPt37Luswk0MKJcFkl-RnSAcbwdv_leBv7T7e2dZIrY3cDN4_GKT4a6Vc7Owz0jRBoLhmuz3TyN6IttvQD_copphzovHxTC3sMTqL0crWHqPb4HdPH3tE_2Wl_gK4JJjX</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2034289056</pqid></control><display><type>article</type><title>A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR -mutated lung adenocarcinoma</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Cao, Y ; Xu, H</creator><creatorcontrib>Cao, Y ; Xu, H</creatorcontrib><description>We aimed to develop a new mutation-predictive scoring system to use in screening for -mutated lung adenocarcinomas (lacs). The study enrolled 279 patients with lac, including 121 patients with wild-type tumours and 158 with -mutated tumours. The Student t-test, chi-square test, or Fisher exact test was applied to discriminate clinical and computed tomography (ct) features between the two groups. Using a principal component analysis (pca) model, we derived predictive coefficients for the presence of mutation in lac. The mutation-predictive score includes sex, smoking history, homogeneity, ground-glass opacity (ggo) on imaging, and the presence of pericardial effusion. The pca predictive model took this form: [Formula: see text]Model scores ranged from 79 to 147. The area under the receiver operating characteristic curve was 0.752 [95% confidence interval (ci): 0.697 to 0.801] in the lac population at the optimal cut-off value of 109, and the sensitivity and specificity were 68.4% (95% ci: 60.5% to 75.5%) and 74.4% (95% ci: 65.6% to 81.9%) respectively. The mutation risk scoring system based on clinical data and ct features is noninvasive and user-friendly. The model appears to frame a positive predictive value and was able to determine the value of repeating a biopsy if tissue is limited.</description><identifier>ISSN: 1718-7729</identifier><identifier>ISSN: 1198-0052</identifier><identifier>EISSN: 1718-7729</identifier><identifier>DOI: 10.3747/co.25.3805</identifier><identifier>PMID: 29719437</identifier><language>eng</language><publisher>Canada: Multimed Inc</publisher><subject>Adenocarcinoma - diagnosis ; Adenocarcinoma - diagnostic imaging ; Adenocarcinoma - genetics ; Adenocarcinoma - pathology ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - genetics ; ErbB Receptors - genetics ; Female ; Genetic Predisposition to Disease ; Humans ; Lung Neoplasms - diagnosis ; Lung Neoplasms - diagnostic imaging ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Mutation ; Neoplasm Staging ; Original ; Predictive Value of Tests ; Retrospective Studies ; Tomography, X-Ray Computed - methods</subject><ispartof>Current oncology (Toronto), 2018-04, Vol.25 (2), p.e132-138</ispartof><rights>2018 Multimed Inc. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-c8bcbb2fc5dc9b7860f0b2032b74eae8c42af646d9efdc88c8b936232c926e773</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927792/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927792/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29719437$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cao, Y</creatorcontrib><creatorcontrib>Xu, H</creatorcontrib><title>A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR -mutated lung adenocarcinoma</title><title>Current oncology (Toronto)</title><addtitle>Curr Oncol</addtitle><description>We aimed to develop a new mutation-predictive scoring system to use in screening for -mutated lung adenocarcinomas (lacs). The study enrolled 279 patients with lac, including 121 patients with wild-type tumours and 158 with -mutated tumours. The Student t-test, chi-square test, or Fisher exact test was applied to discriminate clinical and computed tomography (ct) features between the two groups. Using a principal component analysis (pca) model, we derived predictive coefficients for the presence of mutation in lac. The mutation-predictive score includes sex, smoking history, homogeneity, ground-glass opacity (ggo) on imaging, and the presence of pericardial effusion. The pca predictive model took this form: [Formula: see text]Model scores ranged from 79 to 147. The area under the receiver operating characteristic curve was 0.752 [95% confidence interval (ci): 0.697 to 0.801] in the lac population at the optimal cut-off value of 109, and the sensitivity and specificity were 68.4% (95% ci: 60.5% to 75.5%) and 74.4% (95% ci: 65.6% to 81.9%) respectively. The mutation risk scoring system based on clinical data and ct features is noninvasive and user-friendly. The model appears to frame a positive predictive value and was able to determine the value of repeating a biopsy if tissue is limited.</description><subject>Adenocarcinoma - diagnosis</subject><subject>Adenocarcinoma - diagnostic imaging</subject><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - genetics</subject><subject>ErbB Receptors - genetics</subject><subject>Female</subject><subject>Genetic Predisposition to Disease</subject><subject>Humans</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Neoplasm Staging</subject><subject>Original</subject><subject>Predictive Value of Tests</subject><subject>Retrospective Studies</subject><subject>Tomography, X-Ray Computed - methods</subject><issn>1718-7729</issn><issn>1198-0052</issn><issn>1718-7729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkdFqFTEQhoMotlZvfADJpQh7zCa7m82NUEpbhYIgeh1mJ7Onkd1kTbKV8wY-tntoLfVqhvm_-WfgZ-xtLXZKN_ojxp1sd6oX7TN2Wuu6r7SW5vmT_oS9yvmnEEpprV-yE2l0bRqlT9mfcx7oN18SOY_F3xHPGJMPe54PudDMB8jkeAwcJx88wsQdFOAQHMc4L2vZ1BLnuE-w3B74SFDWRJmPMXHnYR9iPrpdXl9949W8FjguTOs2AkchIiT0Ic7wmr0YYcr05qGesR9Xl98vPlc3X6-_XJzfVKgaWSrsBxwGOWLr0Ay678QoBimUHHRDQD02Esau6Zyh0WHfb7xRnVQSjexIa3XGPt37Luswk0MKJcFkl-RnSAcbwdv_leBv7T7e2dZIrY3cDN4_GKT4a6Vc7Owz0jRBoLhmuz3TyN6IttvQD_copphzovHxTC3sMTqL0crWHqPb4HdPH3tE_2Wl_gK4JJjX</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Cao, Y</creator><creator>Xu, H</creator><general>Multimed Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201804</creationdate><title>A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR -mutated lung adenocarcinoma</title><author>Cao, Y ; Xu, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-c8bcbb2fc5dc9b7860f0b2032b74eae8c42af646d9efdc88c8b936232c926e773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenocarcinoma - diagnosis</topic><topic>Adenocarcinoma - diagnostic imaging</topic><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - genetics</topic><topic>ErbB Receptors - genetics</topic><topic>Female</topic><topic>Genetic Predisposition to Disease</topic><topic>Humans</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Neoplasm Staging</topic><topic>Original</topic><topic>Predictive Value of Tests</topic><topic>Retrospective Studies</topic><topic>Tomography, X-Ray Computed - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, Y</creatorcontrib><creatorcontrib>Xu, H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current oncology (Toronto)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, Y</au><au>Xu, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR -mutated lung adenocarcinoma</atitle><jtitle>Current oncology (Toronto)</jtitle><addtitle>Curr Oncol</addtitle><date>2018-04</date><risdate>2018</risdate><volume>25</volume><issue>2</issue><spage>e132</spage><epage>138</epage><pages>e132-138</pages><issn>1718-7729</issn><issn>1198-0052</issn><eissn>1718-7729</eissn><abstract>We aimed to develop a new mutation-predictive scoring system to use in screening for -mutated lung adenocarcinomas (lacs). The study enrolled 279 patients with lac, including 121 patients with wild-type tumours and 158 with -mutated tumours. The Student t-test, chi-square test, or Fisher exact test was applied to discriminate clinical and computed tomography (ct) features between the two groups. Using a principal component analysis (pca) model, we derived predictive coefficients for the presence of mutation in lac. The mutation-predictive score includes sex, smoking history, homogeneity, ground-glass opacity (ggo) on imaging, and the presence of pericardial effusion. The pca predictive model took this form: [Formula: see text]Model scores ranged from 79 to 147. The area under the receiver operating characteristic curve was 0.752 [95% confidence interval (ci): 0.697 to 0.801] in the lac population at the optimal cut-off value of 109, and the sensitivity and specificity were 68.4% (95% ci: 60.5% to 75.5%) and 74.4% (95% ci: 65.6% to 81.9%) respectively. The mutation risk scoring system based on clinical data and ct features is noninvasive and user-friendly. The model appears to frame a positive predictive value and was able to determine the value of repeating a biopsy if tissue is limited.</abstract><cop>Canada</cop><pub>Multimed Inc</pub><pmid>29719437</pmid><doi>10.3747/co.25.3805</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1718-7729
ispartof Current oncology (Toronto), 2018-04, Vol.25 (2), p.e132-138
issn 1718-7729
1198-0052
1718-7729
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5927792
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Adenocarcinoma - diagnosis
Adenocarcinoma - diagnostic imaging
Adenocarcinoma - genetics
Adenocarcinoma - pathology
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - genetics
ErbB Receptors - genetics
Female
Genetic Predisposition to Disease
Humans
Lung Neoplasms - diagnosis
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Male
Middle Aged
Mutation
Neoplasm Staging
Original
Predictive Value of Tests
Retrospective Studies
Tomography, X-Ray Computed - methods
title A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR -mutated lung adenocarcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T18%3A00%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20new%20predictive%20scoring%20system%20based%20on%20clinical%20data%20and%20computed%20tomography%20features%20for%20diagnosing%20EGFR%20-mutated%20lung%20adenocarcinoma&rft.jtitle=Current%20oncology%20(Toronto)&rft.au=Cao,%20Y&rft.date=2018-04&rft.volume=25&rft.issue=2&rft.spage=e132&rft.epage=138&rft.pages=e132-138&rft.issn=1718-7729&rft.eissn=1718-7729&rft_id=info:doi/10.3747/co.25.3805&rft_dat=%3Cproquest_pubme%3E2034289056%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2034289056&rft_id=info:pmid/29719437&rfr_iscdi=true